This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Read More
This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.
Read More
Analysis: What to Expect From CMS' Inflation Reduction Act Drug Pricing Announcement
August 16th 2024A federal and state policy expert discusses the announcement from the Centers for Medicare & Medicaid Services on the agreement to lower prices for 10 selected drugs due to the Inflation Reduction Act.
Watch
ELM-2 Trial Indicates Odronextamab Effective, Safe in Patients With Follicular Lymphoma
August 15th 2024Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.
Read More
FDA Grants Fast Track Designation for AC699 for Patients With ER+/HER2– Breast Cancer
August 15th 2024AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.
Read More